Caspr2 Encephalitis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CASPR2 Encephalitis is an autoimmune neurological disorder caused by antibodies targeting the Contactin-Associated Protein-like 2 (CASPR2), a member of the neurexin family that is crucial for the formation and maintenance of neuronal synapses[@antibodies], [@severe]. [@severe]
Overview
CASPR2 Encephalitis is recognized as one of the major autoimmune encephalitis syndromes[@antibodies]. It exists on a spectrum with Morvan syndrome, with overlapping clinical features. The condition is part of the voltage-gated potassium channel (VGKC) complex antibody spectrum, though the target antigen is actually CASPR2 rather than the potassium channel itself[@severe]. [@morvan]
This disorder provides important insights into synaptic immunology and the role of axonal proteins in autoimmune neurological disease. Recent research indicates that publications on CASPR2 encephalitis have increased substantially, from 2 in 2010 to 54 in 2025, reflecting growing clinical awareness[^9]. [@morvana]
Pathophysiology
Target Antigen
Contactin-Associated Protein-like 2 (CASPR2) is encoded by the [CNTNAP2 gene](/proteins/cntnap2-protein) and is[@antibodies], [@morvan]:
...
CASPR2 Encephalitis
Introduction
Caspr2 Encephalitis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CASPR2 Encephalitis is an autoimmune neurological disorder caused by antibodies targeting the Contactin-Associated Protein-like 2 (CASPR2), a member of the neurexin family that is crucial for the formation and maintenance of neuronal synapses[@antibodies], [@severe]. [@severe]
Overview
CASPR2 Encephalitis is recognized as one of the major autoimmune encephalitis syndromes[@antibodies]. It exists on a spectrum with Morvan syndrome, with overlapping clinical features. The condition is part of the voltage-gated potassium channel (VGKC) complex antibody spectrum, though the target antigen is actually CASPR2 rather than the potassium channel itself[@severe]. [@morvan]
This disorder provides important insights into synaptic immunology and the role of axonal proteins in autoimmune neurological disease. Recent research indicates that publications on CASPR2 encephalitis have increased substantially, from 2 in 2010 to 54 in 2025, reflecting growing clinical awareness[^9]. [@morvana]
Pathophysiology
Target Antigen
Contactin-Associated Protein-like 2 (CASPR2) is encoded by the [CNTNAP2 gene](/proteins/cntnap2-protein) and is[@antibodies], [@morvan]:
Located in the paranodal region of myelinated [neurons](/entities/neurons)
Critical for maintaining the organization of the voltage-gated potassium channel (VGKC) complex at the axon initial segment
Involved in synaptic transmission and neuronal excitability
Expressed broadly in the central and peripheral nervous systems
Part of the larger [neurexin family](/entities/neurexin-family) of cell adhesion molecules
Immune Mechanisms
Antibody-mediated dysfunction: Anti-CASPR2 IgG antibodies bind to the extracellular domain of CASPR2[@antibodies]
Pathogenic effects: Antibodies disrupt CASPR2 function without causing significant neuronal death
Intrathecal synthesis: Some patients have intrathecal antibody production
T-cell involvement: Both humoral and cellular immune mechanisms contribute[@antibodies]
Complement activation: May play a role in [neuroinflammation](/mechanisms/neuroinflammation)
Associated Tumors
Thymoma: Most commonly associated (~15-20% of cases)[@antibodies], [@morvan]
Small cell lung carcinoma (rare)
Other neoplasms (occasional)
Clinical Features
Core Neurological Symptoms
Encephalopathy[@antibodies], [@morvan]
Cognitive impairment
Memory deficits
Confusion and disorientation
Personality changes
Sleep disturbances
May mimic [neurodegenerative dementia](/diseases/alzheimers-disease) syndromes
Seizures
Generalized tonic-clonic seizures
Focal seizures
Status epilepticus (possible)
Often associated with [temporal lobe](/brain-regions/temporal-lobe) involvement
Movement Disorders[@antibodies], [@morvana]
Tremor (most common)
Myoclonus
Ataxia
Paroxysmal dyskinesias (less common)
May overlap with [extrapyramidal symptoms](/brain-regions/extrapyramidal-system)
Morvan Syndrome Overlap
CASPR2 antibodies can also cause Morvan syndrome, characterized by[@antibodies], [@morvan]:
Encephalopathy
Neuromyotonia (muscle stiffness, fasciculations)
Autonomic dysfunction
Pain
Insomnia
Autonomic Dysfunction
Hyperhidrosis (excessive sweating)
Tachycardia
Blood pressure instability
Gastrointestinal disturbances
Urinary symptoms
Peripheral Nerve Involvement
Neuropathic pain
Muscle cramps
Fasciculations
Sensory disturbances
Diagnosis
Diagnostic Criteria
Subacute onset (less than 3 months) of[@antibodies]:
Cognitive/behavioral changes OR
Seizures OR
Movement disorder
2. Detection of CASPR2 antibodies in serum or [cerebrospinal fluid](/mechanisms/cerebrospinal-fluid)
Laboratory Findings
Serum Testing
CASPR2 antibodies: Highly specific for the syndrome[@antibodies], [@morvan]
VGKC complex antibodies: Often positive (but CASPR2 is the specific target)
EMG/NCV: May show neuromyotonia in Morvan syndrome overlap
Treatment
First-Line Immunotherapy
Corticosteroids[@antibodies]
Methylprednisolone 1g IV daily for 3-5 days
Oral taper
Plasma Exchange
5-7 exchanges
Often effective
Intravenous Immunoglobulin (IVIG)
2 g/kg over 2-5 days
Second-Line Therapy
Rituximab: For refractory cases[^8]
Cyclophosphamide: Alternative
Azathioprine: Maintenance therapy
Tumor Treatment
Thymectomy: If thymoma present
Standard oncological treatment
Symptomatic Management
Antiepileptic drugs for [seizures](/diseases/epilepsy)
Immunomodulatory agents for neuromyotonia
Sleep aids
Pain management
Prognosis
Outcome
Generally favorable prognosis with immunotherapy[@antibodies], [@morvana]
Most patients improve significantly
Residual cognitive deficits possible
Relapse rate: approximately 15-20%[@antibodies], [@morvana]
Prognostic Factors[@antibodies], [@morvana]
Positive:
Early treatment
Tumor removal (when present)
Less severe disease
Negative:
Delayed treatment
Morvan syndrome overlap
Thymoma (may have more severe disease)
Epidemiology
Incidence: Rare (~0.1-0.2 per million per year)
Age: Typically 40-70 years
Sex: Male predominance (4:1)[@antibodies]
Tumor association: ~15-20% have thymoma
Conclusion
CASPR2 encephalitis represents an important and increasingly recognized cause of autoimmune encephalitis. The condition is characterized by antibodies against CASPR2, a neuronal surface protein critical for synaptic function. Clinical manifestations include encephalopathy, seizures, movement disorders, and autonomic dysfunction. Diagnosis relies on detection of CASPR2 antibodies in serum or cerebrospinal fluid, with MRI findings that may include temporal and frontal lobe abnormalities. First-line immunotherapy with corticosteroids, plasma exchange, or IVIG leads to improvement in most patients, though some require second-line agents. The association with thymoma in a subset of patients underscores the importance of tumor screening. Ongoing research continues to refine our understanding of this condition's pathophysiology and optimal management strategies.
The study of Caspr2 Encephalitis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
[Antibodies in Creutzfeldt-Jakob disease: A systematic review of patient characteristics, diagnostics, and clinical implications.](https://pubmed.ncbi.nlm.nih.gov/41548514/) (2026 Apr) - Journal of neuroimmunology
[Severe sleep-related hypoventilation in antibody-positive and antibody-negative autoimmune encephalitis: an emergency.](https://pubmed.ncbi.nlm.nih.gov/41786496/) (2026 Mar 5) - The European respiratory journal
[Morvan Syndrome Masquerading as Anxiety Disorder: A Case Report Highlighting the Importance of Recognizing Organic Signs in Psychiatric Settings.](https://pubmed.ncbi.nlm.nih.gov/41800271/) (2026) - International medical case reports journal
[Morvan syndrome associated with prominent Tau pathology: A clinicopathological case report.](https://pubmed.ncbi.nlm.nih.gov/41793952/) (2026 Feb 27) - Journal of neuroimmunology
[Anti-GABA-AR encephalitis or neuropsychiatric SLE? Avoiding misdiagnosis through comprehensive antibody testing beyond commercial panels.](https://pubmed.ncbi.nlm.nih.gov/41690767/) (2026 Feb 13) - Practical neurology